DJIA 15,973.84 313.66 2.00%
NASDAQ 4,337.51 70.68 1.66%
S&P 500 1,864.78 35.70 1.95%
market minute promo


company name or ticker

GW Pharmaceuticals Beat EPS Estimates, but Is Its Stock a Buy?

A better-than-feared fiscal fourth-quarter loss doesn't offset the risk of clinical trial failures for its marijuana-based medicine.

GW Pharmaceuticals Posts Narrower-than-Expected Q4 Loss

Haemonetics Hit by Russia Weakness, Choppy FY16 View

After-Hours Earnings Report for December 7, 2015 : HRB, CASY, UNFI, HQY, GWPH, ORIG, CENT, MSLI

After-Hours Earnings Report for December 7, 2015 : HRB, CASY, UNFI, HQY, GWPH, ORIG, CENT, MSLI

GW Pharma Issues New Physician Reports on Epidiolex

Why Medical Marijuana Caused GW Pharmaceuticals to Climb 10% in November

Trial results evaluating marijuana-derived medicine for epilepsy could make or break GW investors in 2016.

CVS Health Posts Impressive Q3, Rides High on PBM Strength

What Awaits GW Pharmaceuticals (GWPH) in Q4 Earnings?

The Timing Seems Right For GW Pharmaceuticals

Medtronic-Henry Schein Tie Up for Type 2 Diabetes Products

See More Articles...